-
-
-
-
-
-
-
Supernus Pharma (SUPN) Misses Q4 EPS by 48c, provides guidance
-
-
-
-
-
-
-
BofA Securities Starts Supernus Pharmaceuticals (SUPN) at Buy
-
-
-
-
-
-
-
Supernus Pharmaceuticals (SUPN) PT Raised to $40 at Piper Sandler
-
-
-
-
-
-
-
Supernus Pharma (SUPN) to Acquire Sage Therapeutics (SAGE)
-
-
-
-
-
-
-
Supernus Pharmaceuticals (SUPN) PT Raised to $44 at TD Cowen
-
-
-
-
-
-
-
Supernus Pharma (SUPN) Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
-
-
435,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

